Medical EducationNCT04375254
Neuroscience-based Nomenclature (NbN) as a Teaching Tool
An observational study of Medical Education, run by Hebrew University of Jerusalem at 1 site in Israel.
Trial summary
In recent decades, medical student interest in a career in mental health appear to be in decline, possibly due to the perception that the scientific foundation of psychiatry and psychopharmacology is weaker compared to other fields of medicine. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Medical Education
- What is being tested?
- NbB psychopharmacology training
- How many people
- 100 participants
- Where
- 1 siteIsrael
- Study dates
- 1 May 2020to Sep 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Medical students during fifth year psychiatry clerkship
Who may be able to join
- Medical students during fifth year psychiatry clerkship
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
Israel1 site, 1 recruiting
- Recruiting
Jerusalem Center for Mental Health
Jerusalem
Alzbeta Juven-Wetzler's, MD, 0508801918, alzbetaju@gmail.com
About this study
Official title: The Effect of the Use Of Neuroscience-based Nomenclature (NbN) In The Teaching Of Psychopharmacology on Medical Students Views Toward Psychiatry
In recent decades, medical student interest in a career in mental health appear to be in decline, possibly due to the perception that the scientific foundation of psychiatry and psychopharmacology is weaker compared to other fields of medicine.
In an effort to examine ways of improving the current nomenclature in Psychopharmacology, in 2008 the nomenclature taskforce was initiated, composed of representatives from five international organizations: ECNP - European College of Neuropsychopharmacology, ACNP - American College of Neuropsychopharmacology, AsCNP - Asian College of Neuropsychopharmacology, CINP - International College of Neuropsychopharmacology, IUPHAR - International Union of Basic and Clinical Pharmacology.2 The result of this effort is the Neuroscience based Nomenclature (NbN) - a pharmacologically driven nomenclature that focuses on reflecting current knowledge and on the understanding of the neural system being modified
this research is the first that examine whether putting greater emphasis on neuroscience in the teaching of psychotropics, through the use of the new NbN terminology, achieve the goal of improving medical students views on psychiatry.
Read the detailed description
In recent decades, medical student interest in a career in mental health appear to be in decline1. There are multiple factors responsible for the apparent lack of interest in psychiatry, one of them may be the perception that the scientific foundation of psychiatry and psychopharmacology is weaker compared to other fields of medicine.
As the field of psychopharmacology evolves, the terminology used to describe different classes of medication becomes increasingly convoluted: at a time when the same agent is used for the treatment of several different disorders, the nomenclature in use is indication-based and divided into classes that are disease based - such as Antidepressant, Antipsychotic and Anxiolytics. These classes, in turn, are divided into subclasses like "Atypical" or "Second Generation" - terms that give little information regarding the pharmacological properties of the medication itself.
This discrepancy between the current naming of psychotropics and the way they are used in clinical practice is confusing to both the clinician and the patient - and since it fails to reflect on the current scientific knowledge, may affect the way young medical professionals perceive the profession of psychiatry.
In an effort to examine ways of improving the current nomenclature in Psychopharmacology, in 2008 the nomenclature taskforce was initiated, composed of representatives from five international organizations: ECNP - European College of Neuropsychopharmacology, ACNP - American College of Neuropsychopharmacology, AsCNP - Asian College of Neuropsychopharmacology, CINP - International College of Neuropsychopharmacology, IUPHAR - International Union of Basic and Clinical Pharmacology.2 The result of this effort is the Neuroscience based Nomenclature (NbN) - a pharmacologically driven nomenclature that focuses on reflecting current knowledge and on the understanding of the neural system being modified (''pharmacological domain'') and its mode/mechanism of action (''mode of action'')3. The NbN was widely accepted by both clinicians and leading psychiatric journals4 The need to revise the teaching methods of psychopharmacology was reviewed over the years, with different strategies suggested5. To our knowledge, this research is the first that examine whether putting greater emphasis on neuroscience in the teaching of psychotropics, through the use of a new terminology, achieve the goal of improving medical students views on psychiatry.
- Conditions
- Medical Education
- Being tested
- NbB psychopharmacology training
- Keywords
- psychopharmacology, students views on psychiatry, medical education
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NbB psychopharmacology trainingOther
a two part course in psychopharmacology based on Neuroscience based Nomenclature
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Medical students during psychiatry clerkship who received NbN psychopharmacology training Receives: Other: NbB psychopharmacology training | |
| Control group | Medical students during psychiatry clerkship who received standard psychopharmacology training |
What is being measured
The primary outcome is the main question the study is designed to answer.
NbN influence on medical students views on psychiatry
To examine if Neuroscience-based Nomenclature (NbN) as a teaching-tool for medical students affects their views about the scientific foundation of psychiatry and psychopharmacology.
Measured: May-September 2020
Secondary outcomes (1)
NbN influence on choosing psychiatry as a profession
To examine whether the use of Neuroscience-based Nomenclature (NbN) in the teaching of psychopharmacology can improve medical students' views on choosing a career in psychiatry.
Measured: May-September 2020
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2020
- Study start1 May 2020
- Primary completionAug 2021 (estimated)
- Study completionSep 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Medical EducationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hebrew University of Jerusalem
- Sponsor type
- University, hospital or other
- Collaborators
- Jerusalem Mental Health Center
- Responsible party
- Principal investigator, Daniel Minkin Levy, Hebrew University of Jerusalem
- Investigators
- Zohar Joseph, MD, Study director, Haim Sheba Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04375254
- Sponsor's protocol ID
- 0103wrqw2030
- Status last verified
- Mar 2021
- First submitted
- 3 May 2020
- Last updated
- 16 Mar 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tamaskar P, McGinnis RA. Declining student interest in psychiatry. JAMA. 2002 Apr 10;287(14):1859. No abstract available.
PubMed 11939877Zohar J, Nutt DJ, Kupfer DJ, Moller HJ, Yamawaki S, Spedding M, Stahl SM. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol. 2014 Jul;24(7):1005-14. doi: 10.1016/j.euroneuro.2013.08.004. Epub 2013 Sep 18.
PubMed 24630385Zohar J, Kasper S. Neuroscience-based Nomenclature (NbN): A call for action. World J Biol Psychiatry. 2016 Aug;17(5):318-20. doi: 10.1080/15622975.2016.1193626. Epub 2016 Jul 5. No abstract available.
PubMed 27379490The Lancet Psychiatry. Naming names. Lancet Psychiatry. 2016 Jun;3(6):489. doi: 10.1016/S2215-0366(16)30072-4. No abstract available.
PubMed 27262036Zisook S, Glick ID, Jefferson JW, Wagner KD, Salzman C, Peselow ED, Stahl S. Teaching psychopharmacology: what works and what doesn't. J Clin Psychopharmacol. 2008 Feb;28(1):96-100. doi: 10.1097/jcp.0b013e3181603f6b.
PubMed 18204350
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of the Use Of Neuroscience-based Nomenclature (NbN) In The Teaching Of Psychopharmacology on Medical Students Views Toward Psychiatry
- ClinicalTrials.gov ID
- NCT04375254
- Acronym / sponsor ID
- 0103wrqw2030
- Conditions
- Medical Education
- Keywords
- psychopharmacology, students views on psychiatry, medical education
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Hebrew University of JerusalemUniversity, hospital or other
- Collaborators
- Jerusalem Mental Health Center
- Study start
- 1 May 2020 (actual)
- Primary completion
- Aug 2021 (estimated)
- Study completion
- Sep 2021 (estimated)
- First posted
- 5 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In recent decades, medical student interest in a career in mental health appear to be in decline, possibly due to the perception that the scientific foundation of psychiatry and psychopharmacology is weaker compared to other fields of medicine.
In an effort to examine ways of improving the current nomenclature in Psychopharmacology, in 2008 the nomenclature taskforce was initiated, composed of representatives from five international organizations: ECNP - European College of Neuropsychopharmacology, ACNP - American College of Neuropsychopharmacology, AsCNP - Asian College of Neuropsychopharmacology, CINP - International College of Neuropsychopharmacology, IUPHAR - International Union of Basic and Clinical Pharmacology.2 The result of this effort is the Neuroscience based Nomenclature (NbN) - a pharmacologically driven nomenclature that focuses on reflecting current knowledge and on the understanding of the neural system being modified
this research is the first that examine whether putting greater emphasis on neuroscience in the teaching of psychotropics, through the use of the new NbN terminology, achieve the goal of improving medical students views on psychiatry.
Detailed description
In recent decades, medical student interest in a career in mental health appear to be in decline1. There are multiple factors responsible for the apparent lack of interest in psychiatry, one of them may be the perception that the scientific foundation of psychiatry and psychopharmacology is weaker compared to other fields of medicine.
As the field of psychopharmacology evolves, the terminology used to describe different classes of medication becomes increasingly convoluted: at a time when the same agent is used for the treatment of several different disorders, the nomenclature in use is indication-based and divided into classes that are disease based - such as Antidepressant, Antipsychotic and Anxiolytics. These classes, in turn, are divided into subclasses like "Atypical" or "Second Generation" - terms that give little information regarding the pharmacological properties of the medication itself.
This discrepancy between the current naming of psychotropics and the way they are used in clinical practice is confusing to both the clinician and the patient - and since it fails to reflect on the current scientific knowledge, may affect the way young medical professionals perceive the profession of psychiatry.
In an effort to examine ways of improving the current nomenclature in Psychopharmacology, in 2008 the nomenclature taskforce was initiated, composed of representatives from five international organizations: ECNP - European College of Neuropsychopharmacology, ACNP - American College of Neuropsychopharmacology, AsCNP - Asian College of Neuropsychopharmacology, CINP - International College of Neuropsychopharmacology, IUPHAR - International Union of Basic and Clinical Pharmacology.2 The result of this effort is the Neuroscience based Nomenclature (NbN) - a pharmacologically driven nomenclature that focuses on reflecting current knowledge and on the understanding of the neural system being modified (''pharmacological domain'') and its mode/mechanism of action (''mode of action'')3. The NbN was widely accepted by both clinicians and leading psychiatric journals4 The need to revise the teaching methods of psychopharmacology was reviewed over the years, with different strategies suggested5. To our knowledge, this research is the first that examine whether putting greater emphasis on neuroscience in the teaching of psychotropics, through the use of a new terminology, achieve the goal of improving medical students views on psychiatry.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention group | – | Other: NbB psychopharmacology trainingMedical students during psychiatry clerkship who received NbN psychopharmacology training |
| Control group | – | –Medical students during psychiatry clerkship who received standard psychopharmacology training |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Medical students during fifth year psychiatry clerkship
Key inclusion criteria (1 listed)
- Medical students during fifth year psychiatry clerkship
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NbB psychopharmacology traininga two part course in psychopharmacology based on Neuroscience based Nomenclature | Other | Intervention group |
Primary outcome
NbN influence on medical students views on psychiatry
Time frame: May-September 2020
To examine if Neuroscience-based Nomenclature (NbN) as a teaching-tool for medical students affects their views about the scientific foundation of psychiatry and psychopharmacology.
1 secondary outcome
NbN influence on choosing psychiatry as a profession
Time frame: May-September 2020
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2021.
- Background: PubMed 11939877Tamaskar P, McGinnis RA. Declining student interest in psychiatry. JAMA. 2002 Apr 10;287(14):1859. No abstract available.
- Background: PubMed 24630385Zohar J, Nutt DJ, Kupfer DJ, Moller HJ, Yamawaki S, Spedding M, Stahl SM. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol. 2014 Jul;24(7):1005-14. doi: 10.1016/j.euroneuro.2013.08.004. Epub 2013 Sep 18.
- Background: PubMed 27379490Zohar J, Kasper S. Neuroscience-based Nomenclature (NbN): A call for action. World J Biol Psychiatry. 2016 Aug;17(5):318-20. doi: 10.1080/15622975.2016.1193626. Epub 2016 Jul 5. No abstract available.
- Background: PubMed 27262036The Lancet Psychiatry. Naming names. Lancet Psychiatry. 2016 Jun;3(6):489. doi: 10.1016/S2215-0366(16)30072-4. No abstract available.
- Background: PubMed 18204350Zisook S, Glick ID, Jefferson JW, Wagner KD, Salzman C, Peselow ED, Stahl S. Teaching psychopharmacology: what works and what doesn't. J Clin Psychopharmacol. 2008 Feb;28(1):96-100. doi: 10.1097/jcp.0b013e3181603f6b.
- Individual participant dataSharing planned: No
Related trials for Medical Education
Not yet recruitingObservational study
Federated Learning in Renal Tumor Model
Renal Tumors
Not yet recruiting
Generative AI-Assisted Personalized Feedback for Laparoscopic Skill Learning in Medical Undergraduates
Medical Education
Not yet recruiting
Comparing the Efficacy of a Conversational Agent (QuitBot) Versus Standard Health Education on Smoking Cessation Among Medical Students; A Randomized Controlled Trial.
Conversational Agent, Smoking Cessation
RecruitingObservational study
Artificial Intelligence for Automated Clinical Data Exploration From Electronic Medical Records (CardioMining-AI)
Artificial Intelligence, Machine Learning
Not yet recruiting
AI Smart Glasses Feedback for Intubation Training in Medical Students
Intubation, Intratracheal, Medical Education
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zohar Joseph, MD study director
Haim Sheba Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Medical Education, run by Hebrew University of Jerusalem at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Daniel Levy, MD (0508929655, DANIEL@MINKINLEVY.COM), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
NbN influence on medical students views on psychiatry (time frame: May-September 2020). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04375254, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2021.